Free tool
Stocks above their 200-day average
We cover 36 companies trading above their own 200-day average. The median market value in the group is $6.20B. Across the group, the median move over the past trading day is +0.97%. 100% of the 36 with a 200-day average trade above it. Price change over the past year runs from −13.3% to +65.3% across the middle 80 percent of the group, with a median of +15.4%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
36 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| RHO.DE | Roche Holding AG | $370.84B | Mega cap | +41.42% |
| NOT.DE | Novartis AG | $300.14B | Mega cap | +28.89% |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% |
| NVO.WA | Novo Nordisk A/S | $212.23B | Mega cap | −9.22% |
| NOVO-B.CO | Novo Nordisk A/S | $210.20B | Mega cap | −11.26% |
| NOV.DE | Novo Nordisk A/S | $209.27B | Mega cap | +15.22% |
| ABL.DE | Abbott Laboratories | $200.44B | Mega cap | −10.02% |
| DEMANT.CO | Demant A/S | $9.36B | Mid cap | +17.12% |
| WDH1.DE | Demant A/S | $9.33B | Mid cap | −5.53% |
| KRK.WA | Krka, d. d. | $9.20B | Mid cap | +30.59% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% |
| HLUN-B.CO | H. Lundbeck A/S | $6.47B | Mid cap | +8.99% |
| HLUN-A.CO | H. Lundbeck A/S | $6.40B | Mid cap | +29.71% |
| CTEC.L | Convatec Group PLC | $6.01B | Mid cap | −1.95% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.61B | Mid cap | −9.62% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.08B | Mid cap | +1.26% |
| MCOV-B.ST | Medicover AB (publ) | $3.85B | Mid cap | −8.20% |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% |
| AFX.DE | Carl Zeiss Meditec AG | $3.19B | Mid cap | −24.83% |
| BIOA-B.ST | BioArctic AB (publ) | $3.00B | Mid cap | +12.31% |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% |
| AMBU-B.CO | Ambu A/S | $2.69B | Mid cap | −19.13% |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% |
| ONT.L | Oxford Nanopore Technologies plc | $2.41B | Mid cap | −2.24% |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +27.27% |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.